Avicanna Announces Medical Cannabis Real World Evidence Results and Publication

Executive Summary

• Avicanna announced the peer‑reviewed publication of results from its investigator‑led Medical Cannabis Real‑World Evidence (MCRWE) study in the Canadian Journal of Pain.
• The 24‑week prospective, observational study of chronic pain patients showed statistically significant improvements in pain severity, pain interference, anxiety, depression, and overall quality of life while on physician‑supervised medical cannabis.
• Avicanna highlighted the study as a milestone for generating high‑quality real‑world data to support future randomized trials and inform clinical practice.

Key Details

• Study Design: Prospective, observational cohort; 24‑week follow‑up; patient‑reported outcomes measured with validated pain and mental‑health instruments.
• Population: Chronic pain patients across seven Canadian provinces receiving physician‑authorized medical cannabis via the MyMedi.ca platform.
• Primary Findings: Statistically significant reductions from baseline in pain intensity and pain interference; improvements in anxiety, depressive symptoms, and quality of life.
• Clinical Interpretation: Although changes did not reach established minimal clinically important difference thresholds, directional improvements align with existing real‑world and clinical literature.
• Future Work: The study is ongoing with continued enrollment; further placebo‑controlled randomized trials are needed to define optimal dosing, formulations, and routes of administration.
• Company Role: Avicanna provided patient support services, clinical and data infrastructure, and scientific/medical team assistance for platform operations, without influencing clinical decisions.
• Quotes:
• Dr. Hance Clarke (Principal Investigator) emphasized the importance of health‑care provider supervision and noted observed improvements in pain and related outcomes.
• Karolina Urban, EVP Scientific & Medical Affairs, called the publication an “important milestone” for high‑quality real‑world evidence complementing randomized trials.

Notable Quotes

• “While the term ‘medical cannabis’ is widely used, this study specifically evaluated outcomes among patients using medical cannabis under the supervision of a health‑care provider.” – Dr. Hance Clarke
• “High‑quality, prospective real‑world data can play a critical role in complementing randomized clinical trials, informing clinical practice, and supporting the responsible integration of cannabinoid‑based medicines into evidence‑based care.” – Karolina Urban, PhD